Roche’ Actemra To Inhibit Progression Of Structural Joint Damage In Rheumatoid Arthritis
Disease remission demonstrated at the rate of 30%
Roche has announced one year data from the two year Phase III LITHE study. The study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with Actemra (tocilizumab), experienced a significant inhibition in the progression of structural joint damage, as compared to patients treated with methotrexate alone.
In one year of LITHE study, disease remission was demonstrated in 30% and 47% of patients treated with Actemra 4 mg/kg and 8 mg/kg, respectively, as compared to 8% of patients treated with placebo plus methotrexate.
The study also showed that patients treated with Actemra plus methotrexate, experienced a significant inhibition in the progression of structural joint damage, as compared to patients treated with methotrexate plus placebo.
Related Insight
Suppliers Directory
SGS - Life Science Services
SGS Life Science Services, part of SGS group, has 30 years of experience as a global contract service organisation providing integrated solutions from preclinical activities to phase I-IV trials, bioanalytical and quality control testing.
Suppliers
Biotec Services International Limited - Pharmaceutical Outsourcing Services
Established in 1997, Biotec is a privately owned leading Pharmaceutical services company specialising in cold chain packaging, storage and logistics services.
Suppliers
TNT - Clinical Supply Logistics
TNT provides logistics solutions to the clinical research, diagnostic, pharma, bio-tech and med-tech markets (sectors).
Suppliers
Bioceros - Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins
Bioceros is one of Europe's premier providers of services in pre-clinical development of monoclonal antibodies and generation of GMP-ready protein producing cell lines.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Ideas About the Future of the Innovative Pharmaceutical Industry
Published by Kinapse
White Papers
Quality By Design: The Automated Pharmaceutical Assay
Published by Sotax
White Papers
Outsourcing Your Compliance Headache ‐ BPO
Published by Alliance Life Sciences Consulting Group, Inc.
White Papers
Go Digital or Die
Published by NNIT
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.